Question 1

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC clinical trial (NCT04034459). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this trial compare to other treatment options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC clinical trial (NCT04034459). Contact the study team or your healthcare provider for specific answers.

Question 3

What does the treatment schedule look like, and how often will I need to come in for visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC clinical trial (NCT04034459). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific tests or procedures I will need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC clinical trial (NCT04034459). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience severe side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC clinical trial (NCT04034459). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored throughout the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC clinical trial (NCT04034459). Contact the study team or your healthcare provider for specific answers.

What this study is about